Six Month Data on Long Term Eversense CGM System Show Sustained Accuracy in Longest Pediatric Continuous Sensor Study

Eversense System Also Demonstrates Best Result in CGM Comparative Accuracy Study

Eversense CGM System Now U.S. FDA Approved for Adult Patients with Diabetes

ORLANDO, Fla.–(BUSINESS WIRE)–Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, today announced the presentation by third party researchers of new data from a clinical study evaluating the performance of the Eversense® XL Continuous Glucose Monitoring (CGM) system for up to 180 days in pediatrics and adults with diabetes. Findings were presented on June 22, 2018 at the American Diabetes Association’s (ADA) 78th Scientific Sessions.

Läs hela pressreleasen här.